Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Buildings (2016 - 2023)

China Pharma Holdings (CPHI) has disclosed Buildings for 13 consecutive years, with $9.1 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Buildings fell 7.12% year-over-year to $9.1 million, compared with a TTM value of $9.1 million through Jun 2023, down 7.12%, and an annual FY2022 reading of $9.4 million, down 8.46% over the prior year.
  • Buildings was $9.1 million for Q2 2023 at China Pharma Holdings, down from $9.5 million in the prior quarter.
  • Across five years, Buildings topped out at $10.3 million in Q1 2022 and bottomed at $9.1 million in Q2 2023.
  • Average Buildings over 5 years is $9.7 million, with a median of $9.6 million recorded in 2020.
  • The sharpest move saw Buildings increased 9.59% in 2021, then dropped 8.65% in 2022.
  • Year by year, Buildings stood at $9.4 million in 2019, then increased by 6.92% to $10.0 million in 2020, then rose by 2.34% to $10.3 million in 2021, then fell by 8.46% to $9.4 million in 2022, then decreased by 3.61% to $9.1 million in 2023.
  • Business Quant data shows Buildings for CPHI at $9.1 million in Q2 2023, $9.5 million in Q1 2023, and $9.4 million in Q4 2022.